- Received approval from Israel’s Ministry of Health to initiate two Phase I/II studies to assess the safety and efficacy of INFRADURE™ to treat hepatitis C. These will be the first clinical proof-of-concept studies for the INFRADURE Biopump.
- Enrolled the first patients in a Phase IIa trial in Israel with EPODURE™ to treat anemia in patients with end-stage renal disease who are on dialysis, and presented preliminary data at the American Society of Nephrology’s Kidney Week 2012.
- Expanded the executive management team with the addition of Marvin Garovoy, M.D., as Chief Medical Officer. Dr. Garovoy is a biotechnology and pharmaceutical industry executive with considerable drug development experience at Genentech, XOMA, Hyperion Therapeutics, and Arriva Pharmaceuticals.
- Appointed Sol J. Barer, Ph.D. as Chairman of the Board. Dr. Barer is the former Chairman and Chief Executive Officer of Celgene Corporation.
Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG) (the “Company”), the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today reported financial results for three and nine months ended September 30, 2012. Business Highlights of the Third Quarter and Subsequent Weeks